Snowden Capital Advisors’s ResMed RMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-932
| Closed | -$255K | – | 1320 |
|
|
2025
Q3 | $255K | Buy |
932
+126
| +16% | +$34.4K | 0.01% | 1094 |
|
|
2025
Q2 | $208K | Sell |
806
-516
| -39% | -$123K | 0.01% | 1157 |
|
|
2025
Q1 | $296K | Sell |
1,322
-537
| -29% | -$125K | 0.01% | 987 |
|
|
2024
Q4 | $425K | Buy |
1,859
+35
| +2% | +$8.43K | 0.01% | 833 |
|
|
2024
Q3 | $445K | Buy |
+1,824
| New | +$408K | 0.01% | 823 |
|
|
2023
Q3 | – | Sell |
-4,713
| Closed | -$1.03M | – | 1169 |
|
|
2023
Q2 | $1.03M | Buy |
4,713
+667
| +16% | +$149K | 0.04% | 452 |
|
|
2023
Q1 | $886K | Sell |
4,046
-2,115
| -34% | -$459K | 0.03% | 489 |
|
|
2022
Q4 | $1.28M | Buy |
6,161
+399
| +7% | +$87.7K | 0.05% | 385 |
|
|
2022
Q3 | $1.26M | Buy |
5,762
+238
| +4% | +$54.2K | 0.06% | 371 |
|
|
2022
Q2 | $1.16M | Buy |
+5,524
| New | +$1.18M | 0.05% | 383 |
|
|
2022
Q1 | – | Sell |
-337
| Closed | -$87K | – | 1851 |
|
|
2021
Q4 | $87K | Sell |
337
-1,798
| -84% | -$467K | ﹤0.01% | 888 |
|
|
2021
Q3 | $563K | Sell |
2,135
-97
| -4% | -$26.5K | 0.03% | 503 |
|
|
2021
Q2 | $550K | Sell |
2,232
-441
| -16% | -$92.7K | 0.03% | 515 |
|
|
2021
Q1 | $519K | Buy |
2,673
+125
| +5% | +$25.1K | 0.03% | 486 |
|
|
2020
Q4 | $542K | Sell |
2,548
-92
| -3% | -$18.3K | 0.04% | 422 |
|
|
2020
Q3 | $453K | Sell |
2,640
-645
| -20% | -$119K | 0.04% | 405 |
|
|
2020
Q2 | $631K | Sell |
3,285
-531
| -14% | -$86.9K | 0.05% | 329 |
|
|
2020
Q1 | $562K | Sell |
3,816
-1,909
| -33% | -$304K | 0.06% | 323 |
|
|
2019
Q4 | $887K | Buy |
5,725
+60
| +1% | +$8.65K | 0.08% | 290 |
|
|
2019
Q3 | $765K | Sell |
5,665
-1,156
| -17% | -$151K | 0.08% | 285 |
|
|
2019
Q2 | $832K | Buy |
6,821
+171
| +3% | +$18.9K | 0.09% | 272 |
|
|
2019
Q1 | $691K | Buy |
6,650
+1,595
| +32% | +$165K | 0.08% | 294 |
|
|
2018
Q4 | $576K | Sell |
5,055
-15
| -0.3% | -$1.61K | 0.07% | 293 |
|
|
2018
Q3 | $585K | Buy |
5,070
+252
| +5% | +$27.6K | 0.07% | 307 |
|
|
2018
Q2 | $499K | Buy |
4,818
+625
| +15% | +$63.2K | 0.06% | 304 |
|
|
2018
Q1 | $413K | Buy |
4,193
+518
| +14% | +$49K | 0.06% | 286 |
|
|
2017
Q4 | $311K | Buy |
3,675
+453
| +14% | +$37.4K | 0.04% | 329 |
|
|
2017
Q3 | $248K | Buy |
3,222
+221
| +7% | +$16.9K | 0.04% | 336 |
|
|
2017
Q2 | $234K | Buy |
+3,001
| New | +$215K | 0.04% | 318 |
|
Other funds holding RMD
Snowden Capital Advisors's RMD Position: Q4 2025 in Review
Snowden Capital Advisors sold out of ResMed (RMD) in Q4 2025, closing a stake of 932 shares — an estimated $255K sold.
Snowden Capital Advisors first reported a position in RMD in Q2 2017 and held it in 29 quarters. The position peaked at $1.28M in Q4 2022. 948 funds tracked by Wall St. Rank hold RMD as of Q4 2025.
- Snowden Capital Advisors reported no remaining ResMed position as of Q4 2025 after selling out during the quarter.
- Snowden Capital Advisors sold 932 ResMed shares in Q4 2025, an estimated $255K.
- Snowden Capital Advisors first reported a position in ResMed in Q2 2017 and held it in 29 quarters.
- Snowden Capital Advisors's ResMed position peaked at $1.28M in Q4 2022.
- 948 funds tracked by Wall St. Rank held ResMed as of Q4 2025.
Based on Snowden Capital Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.